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RESUMO 
 
 A metformina (MET) é um fármaco antidiabético utilizado para prevenir a 
liberação de glicose hepática e aumentar a sensibilidade à insulina nos tecidos. 
Pacientes diabéticos com câncer têm, em adição, terapia medicamentosa 
antineoplásica. A doxorrubicina (DXR) é um agente quimioterápico 
antineoplásico que interfere com enzimas topoisomerase II e gera radicais 
livres. A MET isolada (2,5; 5,0; 10,0; 25,0 ou 50,0 mM) foi avaliada quanto à 
mutagenicidade, recombinogenicidade e carcinogenicidade e associado com 
DXR (0,4 mM) para antimutagenicidade, antirecombinogenicidade e 
anticarcinogenicidade, utilizando o “Teste para Detecção de Mutação e 
Recombinação Somática” e o “Teste para Detecção de Clones de Tumores 
Epiteliais” em Drosophila melanogaster. A MET isolada não induziu mutação ou 
recombinação, mas foram observados efeitos moduladores da MET sobre as 
lesões de DNA induzidas pela DXR nas concentrações mais elevadas. Na 
avaliação da carcinogênese, a MET isolada não induziu tumores, mas quando 
associado com DXR, MET também reduziu os tumores induzidos por DXR nas 
concentrações mais elevadas. Sendo assim, nas presentes condições 
experimentais a MET isolada não apresentou efeitos mutagênicos, 
recombinogênicos e carcinogênicos, mas foi capaz de modular o efeito da DXR 
na indução de danos ao DNA e tumores em D. melanogaster. Acredita-se que 
este efeito modulador esteja relacionado principalmente aos efeitos 
antioxidantes, anti-inflamatórios e apoptóticos deste medicamento, embora tais 
efeitos não tenham sido avaliados diretamente. 
 
 
 
 
 
 
 
 
 Palavras-chave: Gene wts, SMART, Teste para detecção de mutação e 
recombinação somática, Tumor, Warts. 
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ABSTRACT 
 
Metformin (MET) is an anti-diabetic drug used to prevent hepatic glucose 
release and increase tissue insulin sensitivity. Diabetic cancer patients are on 
additional therapy with anticancer drugs. Doxorubicin (DXR) is a cancer 
chemotherapeutic agent that interferes with the topoisomerase II enzyme and 
generates free radicals. MET (2.5, 5, 10, 25 or 50 mM) alone was examined for 
mutagenicity,  recombinogenicity and carcinogenicity, and combined with DXR 
(0.4 mM) for antimutagenicity, antirecombinogenicity and anticarcinogenicity, 
using the Somatic Mutation and Recombination Test  and the Test for Detecting 
Epithelial Tumor Clones in Drosophila melanogaster. MET alone did not induce 
mutation or recombination. Modulating effects of MET on DXR-induced DNA 
damage were observed at the highest concentrations. In the evaluation of 
carcinogenesis, MET alone did not induce tumors. When combined with DXR, 
MET also reduced the DXR-induced tumors at the highest concentrations. 
Therefore, in the present experimental conditions, MET alone did not present 
mutagenic/recombinogenic/carcinogenic effects, but it was able to modulate the 
effect of DXR in the induction of DNA damage and of tumors in D. 
melanogaster. It is believed that this modulating effect is mainly related to the 
antioxidant, anti-inflammatory and apoptotic effects of this drug, although such 
effects have not been directly evaluated.  
 
 
 
 
 
 
 
 
 
Keywords: Gene wts, SMART, Somatic mutation and recombination test, 
Tumor, Warts. 
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1. INTRODUCTION 
Metformin (MET) (tradename Glucophage) is an oral anti-diabetic 
drug of the biguanide family widely prescribed as a first choice medication for 
type 2 diabetes mellitus (T2DM). It prevents hepatic glucose release and 
increases tissue insulin sensitivity (MALEK et al., 2015; CHEKI et al., 2016; 
NISHIHAMA et al., 2016). MET has been widely used in the treatment of 
polycystic ovary syndrome and gestational T2DM (AMADOR et al., 2012; 
REECE et al., 2014). Besides, several studies have even suggested that MET 
may have further application in anticancer and antiaging therapies, mainly in 
tumors driven by insulin resistance and obesity (KASZNICKI et al., 2014; 
MARYCZ et al., 2016; TALAULIKAR et al., 2016).  
In mammals, MET is absorbed predominately from the small intestine 
and is excreted unchanged in urine (GRAHAM et al., 2011). The mechanisms of 
MET action are only partially explored and remain controversial (SONG, 2016). 
Several potential mechanisms of action have been proposed: suppression of 
liver glucose production (hepatic gluconeogenesis) by inhibiting mitochondrial 
glycerophosphate dehydrogenase (MADIRAJU et al., 2014); inhibition of the 
mitochondrial respiratory chain (complex I) (OWEN et al., 2000); activation of 
AMP-activated protein kinase (AMPK) (a major cellular regulator of lipid and 
glucose metabolism) in hepatocytes, through liver kinase B1 (ZHOU et al., 
2001); suppression of hepatic glucagon signaling by decreasing production of 
cyclic adenosine monophosphate (cAMP) (MILLER et al., 2013);  and changes 
in the gut microbiota and their metabolic pathways (LEE and KO, 2014).  
MET may exert antineoplastic effects through: AMPK-mediated or 
AMPK-independent inhibition of mammalian target of rapamycin (mTOR), which 
is up-regulated in many cancer tissues (HAN et al., 2015); or blocking migration 
and invasion of tumor cells by inhibition of matrix metalloproteinase-9 activation 
through a calcium and protein kinase Cα-dependent pathway (HWANG and 
JEONG, 2010). 
Several studies indicate that MET has also antioxidant (HOU et al., 
2010; ALGIRE et al., 2012; ASHOUR et al., 2012; NA et al., 2013; YANG et al., 
2014b; VILELA et al., 2016), anti-inflammatory (WOO et al., 2014; JIN et al., 
2015; CAMERON et al., 2016; ZHOU et al., 2016), and apoptotic effects (FANG 
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et al., 2014; TAKAHASHI et al., 2014; HAN et al., 2015; SUN et al., 2016). 
Regarding the mutagenic/clastogenic/recombinogenic potential of MET, 
literature data are conflicting. Some studies have shown that MET is not 
genotoxic in vivo or in vitro (ALEISA et al., 2007; ATTIA et al., 2009; AMADOR 
et al., 2012; MALEK et al., 2015; SANT’ANNA et al., 2013; CHEKI et al., 2016; 
ULLAH et al., 2016), non-recombinogenic (SANT’ANNA et al., 2013) and may 
protect from genomic instability (ATTIA et al., 2009; CHEKI et al., 2016; ULLAH 
et al., 2016). Nevertheless, MET induced genotoxicity in rodent cells in vitro 
(AMADOR et al., 2012) and in T2DM patients in vivo (HARISHANKAR et al., 
2015). 
Hyperglycemia is commonly observed in a wide variety of diseases, 
including cancer. Diabetic cancer patients are on additional therapy with 
anticancer drugs (ALEISA et al., 2007).  
Doxorubicin (DXR) (also called Adriamycin ® or 14-
hydroxydaunorubicin) is an anthracyline drug first extracted from Streptomyces 
peucetius ATCC 27952 that is used to treat many different types of cancer 
(MALLA et al., 2010). Nevertheless, its use as an antitumor therapeutic agent is 
limited due to its cardiotoxic effects (SHETA et al., 2016). DXR may intercalate 
on DNA and induce formation of DNA adducts at active promoter sites, 
increasing torsional stress and enhancing nucleosome turnover.  Furthermore, it 
may trap topoisomerase II at breakage sites, causing double strand breaks. 
Enhanced nucleosome turnover might increase the exposure of DNA to reactive 
oxygen species (ROS) resulting in DNA damage and cell death (YANG et al., 
2014a). Previous studies have demonstrated that MET may have protective 
effects against DXR-induced cardiotoxicity and clastogenicity (ALEISA et al., 
2007; SHETA et al., 2016). 
In the present study, the wing Somatic Mutation and Recombination 
Test (SMART) was used to assess MET mutagenicity and its anti-mutagenic 
potential against DXR-induced mutagenicity. We also investigated the 
carcinogenic potential of MET alone and its anti-carcinogenic potential against 
DXR-induced carcinogenicity using the Test for Detection of Epithelial Tumor 
Clones (Warts) in D. melanogaster. 
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2. OBJECTIVE 
In the present study, the wing Somatic Mutation and Recombination 
Test (SMART) was used to assess MET mutagenicity and its anti-mutagenic 
potential against DXR-induced mutagenicity. We also investigated the 
carcinogenic potential of MET alone and its anti-carcinogenic potential against 
DXR-induced carcinogenicity using the Test for Detection of Epithelial Tumor 
Clones (Warts) in D. melanogaster. 
 
 
3. MATERIAL AND METHODS 
 
3.1. Chemical agents 
Metformin (N, N′-dimethylbiguanide; CAS 657-24-9) was purchased 
from Merck, Rio de Janeiro, Brazil. Doxorubicin (DXR; CAS 25316-40-9), 
commercially known as Adriblastina®, was produced by Actavis Italy, Nerviano, 
Italy. The solutions were always prepared immediately before use with ultrapure 
water obtained from a MilliQ system (Millipore; Vimodrome, Milan, Italy). The 
structural formulas of these substances are shown in Fig. 1. 
 
3.2. Strains and stock 
In this study the following strains of D. Melanogaster were used: [1] 
multiple wing hairs (mwh/mwh); [2] flare-3 (flr3/In(3LR)TM3, ri pp sep l(3)89Aa 
bx34e and BdS); [3] ORR; flare-3 (ORR/ORR; flr3/In(3LR)TM3, ri pp sep l(3)89Aa 
bx34e and BdS); and [4] wtsTM3, Sb1. These strains were maintained in glass 
vials filled with a maintenance medium (i.e., banana, sucrose, yeast and 
methylparaben) under light/dark cycles (12 h:12 h), at 25 ± 1ºC and 
approximately 60% humidity in a BOD-type chamber (Model: SL224, SOLAB – 
Equipamentos para Laboratórios Ltda., São Paulo, SP, Brazil). 
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3.3. Somatic Mutation and Recombination Test – SMART 
 
3.3.1. Crosses and treatments  
The SMART assay allows the detection of different genetic end-
points, using two different strains of D. melanogaster that carry specific genetic 
markers (mwh and flr3) on the left arm of chromosome 3 (GRAF et al., 1984). 
Two crosses were carried out to produce the experimental larval 
progeny: (1) Standard cross (ST): mwh/mwh males crossed with 
flr3/In(3LR)TM3, ri pp sep l(3)89Aa bx34e and BdS virgin females (GRAF et al., 
1984; GRAF et al., 1989); (2) High bioactivation (HB) cross: mwh/mwh males 
crossed with ORR/ORR; flr3/In(3LR)TM3, ri pp sep l(3)89Aa bx34e and BdS 
virgin females (GRAF and VAN SCHAIK, 1992). The two crosses produce two 
types of flies: marker trans-heterozygous (MH) flies (mwh +/+ flr3) and balancer-
heterozygous (BH) flies (mwh+/+TM3, BdS).  
Detailed information on genetic symbols can be found in Lindsley 
and Zimm (1992). The ST cross uses strains carrying basal levels of the 
metabolizing cytochrome P450 enzyme (Cyp6A2) and is used to detect direct-
acting genotoxins. The HB cross uses strains with high levels of Cyp6A2 and is 
used to detect indirect-acting genotoxins that exert their genotoxic activity only 
when metabolized (GRAF and van SCHAIK, 1992; SANER et al., 1996; 
REZENDE et al., 2011). 
 
3.3.2. Experimental procedure 
Eggs, from both crosses, were collected for 8 h in culture bottles 
containing a solid agar base (5% w/v agar agar in water) covered with a thick 
layer of live baker’s yeast supplemented with sucrose. Approximately 72 h after 
the end of the egg-laying stage, larvae were collected and distributed in four 
sets of vials for each cross with 1.5 g of mashed potato flakes and 5 mL of a 
solution containing metformin alone (at a final concentration of 2.5, 5, 10, 25 or 
50 mM or with DXR at 0.4 mM). Negative (ultrapure water) and positive 
doxorubicin (DXR 0.4 mM) controls were included.  
The larvae were counted before distribution into two series of these 
vials. The number of hatched flies was used to calculate the survival rates upon 
exposure. The experiments were conducted at a temperature of 25 ± 1oC at a 
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relative humidity of 60%. The hatching adult flies were collected from the 
treatment vials and stored in 70% ethanol. The wings were removed and 
mounted in Faure’s solution on microscope slides and inspected under 400X 
magnification for the presence of spots. 
On marker-heterozygous (MH) wings (mwh/flr3) three different 
categories of spots can be observed: (i) small single spots (1–2 cells in size) 
and (ii) large single spots (more than two cells), expressing either the multiple 
wing hairs (mwh) or the flare (flr3) phenotype, as well as (iii) twin spots, 
consisting of both mwh and flr3 sub clones. 
On balancer heterozygous (BH) wings (mwh/TM3) only mwh single 
spots can be observed, as the inverted TM3 balancer chromosome does not 
carry flr3 or any other suitable marker mutation. While in the MH flies mutant 
clones can be originated by somatic point mutation, chromosome aberration 
and/or mitotic recombination, in the BH genotype this last genotoxic event is 
suppressed due to the presence of multiple inversions in the TM3 balancer 
chromosome. Through comparison of these two genotypes, it is possible to 
quantify the recombinogenic action of the drug tested (FREI et al., 1992). 
 
3.3.3. Statistical Analysis 
The frequency of each type of spot (small single, large single or twin) 
and the total frequency of spots per fly for each treatment were compared pair-
wise (i.e., negative control versus metformin; positive control (DXR) alone 
versus DXR plus metformin) according to Kastenbaum and Bowman (1970) 
with p = 0.05 (FREI and WURGLER,     ,     ). The data were initially 
evaluated according to the multiple-decision procedure of Frei and   rgler 
(1988). Afterwards, to exclude false positive and inconclusive results due to 
overdispersion of the data, the U-test of Wilcoxon, Mann, and Whitney was 
applied, resulting in two different diagnoses: positive and negative (FREI and 
  R  ER, 1995).  
Based on the clone induction frequency per 105 cells, the 
recombinogenic activity was calculated as follows. Frequency of mutation (FM) 
= frequency of clones in BH flies/frequency of clones in MH flies. Frequency of 
recombination (FR) = 1 – frequency of mutation (FM). Frequencies of total spots 
(FT) = total spots observed in MH flies (considering mwh and flr3 spots)/number 
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of flies (SANTOS et al., 1999; SINIGAGLIA et al., 2004, 2006).  
Based on the control-corrected spot frequencies per 105 cells, the 
percentage of metformin inhibition was calculated as: (DXR alone – metformin 
plus DXR/DXR alone) – 100 (Abraham, 1994). 
 
3.4. Test for the detection of epithelial tumor clones in Drosophila 
melanogaster (Warts) 
 
3.4.1. Crosses and treatments 
To obtain wts +/+ mwh heterozygotic larvae, virgin females wtsTM3, 
Sb1 were crossed with mwh/mwh males (Nepomuceno, 2015). The eggs of the 
descendants were collected as in the SMART assay. After approximately 72 h, 
third-instar larvae from this cross were treated. The larvae were placed in glass 
flasks containing 1.5 g of instant mashed potatoes (Hikari® brand, São Paulo, 
Brazil) culture medium, and 5 mL of a solution containing metformin (2.5; 5; 10; 
25 or 50 mM). The concentrations were chosen based on the survival rates of a 
dose-response test performed by Slack et al. (2012). Negative (reverse osmosis 
water) and positive (Doxorubicin 0.4 mM) controls were included.  
The larvae were distributed into two series of vials, and they were 
allowed to feed on the above medium for approximately 48 h. Only adult flies 
without the chromosome balancer (TM3, Sb1), characterized by the absence of 
truncated bristles, were used. The hatched flies were stored in 70% ethanol. 
 
3.4.2. Analysis of the flies   
Adult flies of the wts +/+ mwh genotype, which have wild hairs (long 
and thin), were analyzed for tumor (wart) presence. The flies were observed 
using a stereoscopic magnifying glass and only tumors that were large enough 
to unmistakably classify were recorded. Each fly, immersed in glycerin 
(C3H8O3), was analyzed using a thin brush. The tumor frequency was calculated 
as the number of tumors/number of wts +/+ mwh flies (NEPOMUCENO, 2015). 
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3.4.3. Statistical Analysis 
The carcinogenic and the anticarcinogenic potentials of metformin 
were validated by the Mann, Whitney and Wilcoxon nonparametric U test, using 
α=0.05 level of significance. 
 
4. RESULTS 
The objective of the present study was to evaluate the mutagenic, 
recombinogenic and carcinogenic effect of metformin, as well as its possible 
modulatory effects on DNA induced damage induced by Doxorubicin (DXR). In 
this study, third-instar larvae (72 + 4h) from both tests, Somatic Mutation and 
Recombination Test (SMART) and Epithelial Tumor Clone Detection Test 
(WTS) were treated for approximately 48 h. Each treatment was done in 
duplicate. The data were collected after verification that there were no 
significant differences between the replicates.  
The concentrations used of metformin alone or in combination with 
DXR were selected based on survival assay. The survival rates are presented 
in Table 1. According to the survival rate, it was possible to observe that none of 
the concentrations tested, including the controls, showed toxic effect. All rates 
were higher than 85% (p > 0.05). Similar results were observed by Slack et al. 
(2012). There was no significant reduction in the number of individuals treated 
with concentrations of 1, 2.5, 5, 10, 25 or 50 mM of metformin. On the other 
hand, there was a significant decrease in the survival of individuals treated with 
100 mM. 
 
4.1. SMART 
The Somatic Mutation and Recombination Test (SMART) in wing 
somatic cells of D. melanogaster was used to assess the mutagenic and 
recombinogenic potential of metformin and its possible effects on modulating 
the damage induced by doxorubicin (DXR). The results for the marker 
transheterozygous (MH) and balancer heterozygous (BH) descendants, derived 
from the Standard Cross (ST), treated with different concentrations of metformin 
alone or in combination with DXR are shown in Table 2. 
The DXR treatment, as expected, induced positive results for all 
categories of spots when compared to the negative control (p < 0.05). While the 
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positive control (DXR) significantly increased the number of spots in all classes 
of stains (single, large, twin and total) when compared to the negative control 
(ultrapure water). The statistically significant increases of twin spots indicate the 
recombinogenic activity of DXR.  
As shown in Table 1, none of the five metformin concentrations (2.5, 
5, 10, 25 or 50 mM) evaluated, significantly increased the total number of 
mutant spots (p> 0.05) in MH descendants of ST cross, when compared to the 
negative control. 
Metformin suppressed the DNA damage induced by DXR without 
interfering in the recombinogenic activity of DXR (Figure 2). The simultaneous 
administration of DXR (0.4 mM) with metformin (2.5; 5; 10; 25 or 50 mM) 
presented a statistically significant reduction for the following categories of 
spots: small single, large single and total of spots when compared with DXR 
alone (p < 0.05). On the other hand, the same result was not observed for twin 
spots. 
The simultaneous treatment with metformin (2.5, 5; 10; 25 or 50) and 
DXR was ineffective in the inhibition of all spot classes when compared to DXR 
alone (p > 0.05). Nevertheless, metformin (25 and 50 mM) reduced significantly 
the total frequency of spots (42.23% and 42.55% respectively).  
Based on the clone induction frequency per 105 cells, we compared 
the number of observed spots in the MH and BH flies and quantified the 
contribution (%) of mutation and recombination to the total number of observed 
spots (FREI et al., 1992; GRAF et al., 1992; ABRAHAM, 1994). This procedure 
enabled us to quantify the contribution of mutagenic and recombinogenic events 
to the final genotoxicity observed (FREI et al., 1992; GRAF et al., 1992). 
In the BH individuals of the ST cross, DXR (0.4 mM) induced a 
significant increase in the mutant spot frequency relative to the negative control. 
The wings of the BH flies resulting from the simultaneous application of 
metformin 25 or 50 mM with DXR (0.4 mM) were also scored. We found that the 
induced spots were mainly due to recombination, but metformin does not affect 
the recombinogenic activity of DXR (Figure 2). 
The results of the HB cross of the SMART assay are depicted in 
Table 3. The results obtained with the MH individuals treated with metformin 
alone were negative at all tested concentrations. DXR statistically increased, as 
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expected, all categories of spots when compared to the negative control. Once 
more, the recombinogenic activity was the major response to DXR-induced 
DNA damage (94.60%).  
When administered with DXR, only the highest concentration of 
metformin (50 mM) was found to statistically inhibit DXR-induced DNA damage 
(33.15%). Although the total number of spots diminished, there was an increase 
of recombination contribution to the total number of spots. It was again 
observed that metformin exhibits only antimutagenic activity and does not 
interfere with the recombinogenicity (Figure 2) 
 
4.2. WTS 
The epithelial tumor detection test in D. Melanogaster was used in 
order to estimate the contribution of somatic recombination in the process of 
cancer cell development. The present study evaluated the carcinogenic 
potential of metformin (2.5; 5; 10; 25 or 50 mM) as well as its protective effects 
in the presence of DXR (0.4 mM). A total of 200 flies of both sexes were 
analyzed in each group. The presence of epithelial tumor in different 
appendages was counted and the total frequency of epithelial tumor and the 
tumor rate in the appendices of the flies were compared pair-wise. 
The results for tumor frequencies are shown in Table 4. In all 
concentrations evaluated, metformin was not able to induce a significant 
increase (p > 0.05) in the total tumor frequency of epithelial tumor, when 
compared to the negative control. However, DXR (0.4 mM) statistically 
increased the frequency of tumors in all appendices. For all treated series, the 
highest frequencies of tumors are located in the wing and in the body of the 
flies.  
In order to evaluate the anticarcinogenic effect of metformin, the 
same simultaneous treatments performed in SMART assay were repeated. 
Metformin associated with DXR (0.4), regardless of the concentration (2.5; 5; 
10; 25 or 50), was able to reduce the total tumor frequency. However, the 
reduction was not dose-dependent. 
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5. DISCUSSION 
In the present study, the mutagenic and/or recombinogenic activities 
of MET alone, as well as its modulatory effects against DXR-induced DNA 
damage were evaluated using the ST and HB crosses of the Somatic Mutation 
and Recombination Test (SMART) in D. melanogaster. Similar results were 
obtained in both crosses. MET alone did not alter the frequency of spontaneous 
mutant spots in this test system, but displayed a modulating effect on DNA 
damage induced by DXR. 
The reference mutagen (DXR) significantly increased the frequency 
of all mutant spot categories. Previous studies using the Drosophila wing 
SMART demonstrated that the main genetic contribution of DXR is its ability to 
induce recombination (COSTA et al., 2011; ORSOLIN et al., 2015, 2016). While 
MET was able to significantly reduce the total frequency of mutant spots in the 
two highest concentrations of the ST crosses (25 and 50 mM) and in the highest 
concentration of the HB crosses (50 mM), this drug was not able to alter the 
recombination pattern of DXR.  
The differences in the results observed with DXR in both crosses are 
related to the basal and high levels of metabolic enzymes of cytochrome P450 
complex present in the ST and HB crosses, respectively. Cytochrome P450 
enzymes (CYPs) form one of the enzyme families involved in the metabolism of 
xenobiotics, including drug compounds. CYPs comprise many isoforms which 
catalyze a wide variety of reactions leading to different metabolites (OLSEN et 
al., 2015). The first cytochrome P450 cloned from Drosophila was the phase I 
enzyme cytochrome P450 6A2, which presents a peak of expression in the third 
larval and pupal stage. CYP6A2 mRNA was found to be present in the 
insecticide-resistant strain [OR(R)] at higher levels than in the insecticide-
sensitive (flr3) strain (SANER et al., 1996), which may explain the different 
frequencies of mutations observed with DXR in the ST and HB crosses. 
Although the OR(R) lineage has higher levels of cytochrome P450 
enzymes than the flr3 strain, similar results were found in both crosses (ST and 
HB) when third-stage larvae were treated with MET alone, demonstrating that 
MET is not metabolized by CYPs. Likewise, and for that reason, no significant 
differences were observed in the percentages of inhibition of the mutant spot 
frequencies between individuals from ST and HB crosses treated 
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simultaneously with MET plus DXR. Thus, similar percentages of inhibition 
(37.33% and 34.59%) were found for individuals treated with MET 50 mM + 
DXR in the ST and HB crosses. This result is in line with literature data that 
MET is excreted unchanged in the urine and there is no evidence that it is 
metabolized (GRAHAM et al., 2011).  
Previous studies have shown that MET (100, 500 or 2500 mg/kg) 
was neither genotoxic nor cytotoxic for normal and diabetic rats, and may 
protect from genomic instability induced by reactive oxygen species produced in 
T2DM (ATTIA et al., 2009). The clastogenic property of MET (concentrations 
ranging from 6.25 μg/ml to 1600 μg/ml) and of the analgesic drug Celecoxib 
(ranging from 2.34 μg/ml to 600 μg/ml) alone and in combination was assayed 
in human peripheral blood mononuclear cells (lymphocytes and monocytes) 
using single cell gel electrophoresis (Comet Assay). MET produced non-
significant DNA damage, while Celecoxib produced significant DNA damage. 
The DNA damage or DNA tail protrusions by combinations of both drugs were 
less than what was observed with Celecoxib alone (ULLAH et al., 2016).   
MET also was not clastogenic, but significantly decreased the 
frequency of X-radiation-induced chromosomal aberrations (dicentrics, acentric 
fragments, rings, micronuclei, and nucleoplasmic bridges) and the apoptotic 
incidence when human lymphocytes were pre-treated with MET (10 and 50 μM) 
for 2 h and irradiated with 6MV X-rays (CHEKI et al., 2016). Nevertheless, when 
mutagenic effect was determined by performing bacterial reverse mutation 
assay (Ames test) using Salmonella typhimurium mutated strains TA-100 and 
TA-98 with and without metabolic activation, MET and Celecoxib had no 
mutagenic effects, but their combined concentration exhibited mutagenic 
potential at much higher doses (ULLAH et al., 2016). 
The carcinogenic potential of MET alone and its anti-carcinogenic 
potential against DXR-induced carcinogenicity were evaluated by the test for 
detection of epithelial tumor clones (Warts) in D. melanogaster. As expected, 
MET alone, at the same concentrations used in this study to assess its 
mutagenic/recombinogenic effects, did not induce tumor formation. On the other 
hand, MET displayed modulatory effects on the DXR-induced tumors at the four 
highest concentrations (5-50 mM). The significant reduction of tumors by MET 
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may have occurred by the same mechanisms involved in modulating the 
damage induced by DXR.  
Although there is a lack of data in the scientific literature regarding to 
the use of metiformin and the increased or reduced risk of cancer, Franciosi et 
al. (2013) concluded, in a systematic review, that MET might be associated with 
a significant reduction in the risk of cancer and cancer-related mortality. 
There is a large amount of evidence indicating that DNA damage is a 
major primary cause of cancer. DNA damage gives rise to mutations and 
epimutations that can cause progression to cancer. The importance of DNA 
damage and repair to the induction of carcinogenesis became evident when it 
was recognized that almost all carcinogens also are mutagens. Thus, all the 
effects of carcinogenic chemicals on tumor induction can be explained by the 
DNA damage that they cause and by the errors introduced into DNA during the 
repair of this damage (LODISH et al., 2000; BERNSTEIN et al., 2013). Algire et 
al. (2012) considered the possibility that cancer risk reduction by MET could be 
attributed at least in part to inhibition of mutagenesis. Thus, it is likely that the 
modulatory mechanisms exerted by MET on the reduction of mutant spots 
induced by DXR (antimutagenic effect) protected the DNA from a mutation and, 
consequently, also protected it from the onset of tumors.  
The mechanisms by which MET reduces DNA damage and tumor 
formation induced by DXR were not directly evaluated in the present study. The 
hypothesis about the effect of MET when associated with DXR is that it has 
different characteristics capable of modulating the damage induced by this 
chemotherapeutic agent.   
One of the characteristics of MET, which may be related to the 
modulation of DNA damage and/or DXR-induced tumors, is its antioxidant 
capacity. Previous studies demonstrated that MET significantly reduces 
intracellular ROS levels by increasing the expression of the antioxidant 
thioredoxin (Trx) through the AMP-activated protein kinase (AMPK) pathway. 
MET-regulated Trx at the transcriptional level and forkhead transcription factor 3 
(FOXO3) were involved in this process (HOU et al., 2010); it attenuates 
paraquat-induced elevations in reactive oxygen species (ROS), and related 
DNA damage and mutations in AMPKα+/+ and AMPKα−/− mouse embryonic 
fibroblasts (ALGIRE et al., 2012); reduced oxidative stress-related accumulation 
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of DNA damage on intestinal stem cells derived from Drosophila midgut (NA et 
al., 2013).  
Besides, the effects of MET on AMPK and on nuclear factor-erythroid 
2-related factor 2 (Nrf2) signaling, which plays a crucial role in protecting cells 
from oxidative damage, were tested in C2C12 mouse myoblasts cells in vitro 
and in Male C57BL/6J mice in vivo. MET activated AMPK and Nrf2 signaling 
and induced the expression of antioxidant genes NQO1 and γGCSm in C2C12 
cells, and activated Nrf2 signaling and induced the expression of antioxidant 
genes such as HO1 and SOD, and resulted in increased GSH level in mouse 
liver and skeletal muscle tissues, demonstrating that MET activated Nrf2 
signaling and enhanced the tissue antioxidant capacity (YANG et al., 2014b). 
Clinical use of DXR is limited by its cardiotoxic side effects. Recent 
studies demonstrate that MET successfully prevents DXR-induced cardiotoxicity 
in vivo by inhibiting DXR-induced oxidative stress, energy starvation, and 
depletion of intramitochondrial coenzyme A (CoA-SH) (ASHOUR et al., 2012); 
or through its modulation of ferritin heavy chain (FHC) (ASENSIO-LÓPEZ et al., 
2013; 2014).  
However, it is possible that the modulatory effect exerted by MET 
may also be related to its anti-inflammatory effect. Inflammatory mediators are 
implicated in the production of ROS (KIM and CHOI, 2012). Recent studies 
have shown that MET protects against acute inﬂammatory responses by 
inhibiting ROS generation, ﬂuid extravasation, and neutrophil migration 
(PANDEY and KUMAR, 2016). MET inhibits advanced glycation end (AGEs) 
products-induced inflammatory response in murine macrophages partly through 
AMPK activation and RA E/NFκB (involved in A Es-induced macrophage 
inflammatory activation) pathway suppression (JIN et al., 2015; ZHOU et al., 
2016).  
MET may also reduce the frequency of DXR-induced mutant spots 
and/or tumors by regulating the expression of different genes involved in the 
apoptosis process. Takahashi et al. (2014) demonstrated that MET may 
suppress Ishikawa endometrial cancer cell growth through the induction of cell 
cycle arrest and concomitant caspase-dependent apoptosis and enhanced 
autophagic flux. On the other hand, Sun et al. (2016) identified a novel signaling 
pathway that involves AMPK, p53, miR-23a, and FOXA1 in MET-caused 
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apoptosis in human hepatocellular carcinoma HepG2 cells; and Fang et al. 
(2014) demonstrated that MET inhibited A498 cell proliferation in a time- and 
dose-dependent manner, as well as induced the activation of AMP-activated 
protein kinase and promoted A498 cell apoptosis mediated by the 
downregulation of B-cell lymphoma 2 and concurrent upregulation of Bcl-2-
associated X protein.  
 
6. CONCLUSION  
The results observed in our study allow us to conclude that, under 
the experimental conditions, MET has no mutagenic, recombinogenic or 
carcinogenic effects, but modulates the effects of DXR in the induction of DNA 
damage and tumors in D. melanogaster.  Based on literature data, we may 
suggest that the modulatory effects of MET may be explained by its anti-oxidant 
and anti-inflammatory capacities, besides apoptotic induction. 
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Figure 1.  Structural formulas of the substances used in the present study: A. 
Metformin (MET); B. Doxorubicin (DXR) (Oliveira et al., 2017, in Food and 
Chemical Toxicology 106, 283-291). 
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Table 1. Survival rates upon exposure to different concentrations of metformin 
(MET) in combination with doxorubicin (DXR) relative to control group (ultrapure 
water) in the wing Somatic Mutation and Recombination Test (ST and HB 
crosses) and in the Test for Detection of Epithelial Tumor Clones (warts) in D. 
melanogaster. 
 
 
Treatments  ST cross  HB cross  Warts cross 
DXR 
(mM) 
MET 
(mM) 
Survival 
(%) 
p-
value 
Survival 
(%) 
p-
value 
Survival 
(%) 
p-
value 
0 0  100 >0.05  100 >0.05  94 >0.05 
0 2.5  100 >0.05  100 >0.05  97 >0.05 
0 5  97 >0.05  100 >0.05  100 >0.05 
0 10  100 >0.05  97 >0.05  96 >0.05 
0 25  100 >0.05  100 >0.05  100 >0.05 
0 50  100 >0.05  90 >0.05  92 >0.05 
0,4 0  97 >0.05  94 >0.05  95 >0.05 
0,4 2.5  100 >0.05  100 >0.05  98 >0.05 
0,4 5  100 >0.05  100 >0.05  100 >0.05 
0,4 10  100 >0.05  97 >0.05  100 >0.05 
0,4 25  90 >0.05  97 >0.05  94 >0.05 
0,4 50  87 >0.05  87 >0.05  86 >0.05 
 
Statistical comparisons of survival rates were made by using Chi-square test for 
ratios for independent samples (Ref.: Oliveira et al., 2017, in Food and 
Chemical Toxicology 106, 283-291). 
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Table 4. Tumor clone frequency observed in D. melanogaster heterozygote for the wts tumor suppressor gene, after chronic 
treatment of larvae with metformin (MET), doxorubicin (DXR, positive control), and ultrapure water (negative control). 
Statistical diagnosis according to the Mann–Whitney Test;  evel of significance p≤0.0 ;  
* different from negative control (ultrapure water);  
** different from the positive control (DXR, 0.4 mM); 
(Oliveira et al., 2017, in Food and Chemical Toxicology 106, 283-291). 
Treatments 
Number 
of flies 
Frequency of tumors analyzed (total of tumors) 
 Frequency of 
tumor/fly 
(Total) 
Reductio
n (%) 
MET 
(mM) 
DXR 
(mM) 
Eye Head Wing Body Leg Halter 
0 0 200 0.01 (03) 0.04 (09) 0.06 (13) 0.07 (15) 0.03 (07) 0.01 (02) 0.24 (49)  
0 0.4 200 0.64  (128)* 0.52 (104)* 2.73 (546)* 1.25 (250)* 0.98 (196)* 0.38 (76)* 6.49 (1300)*  
2.5 0 200 0.01 (03) 0.04 (08) 0.03 (07) 0.08 (16) 0.02 (05) 0.00 (00) 0.19 (39)   
5 0 200 0.01 (02) 0.02 (04) 0.02 (05) 0.06 (12) 0.05 (11) 0.01 (03) 0.18 (37)   
10 0 200 0.02 (04) 0.02 (04) 0.03 (07) 0.08 (16) 0.03 (07) 0.00 (01) 0.19 (39)   
25 0 200 0.01 (02) 0.02 (04) 0.04 (09) 0.04 (09) 0.05 (11) 0.01 (02) 0.18 (37)   
50 0 200 0.00 (01) 0.02 (05) 0.07 (15) 0.05 (10) 0.02 (05) 0.00 (01) 0.18 (37)   
2.5 0.4 200 0.60 (121) 0.55 (110) 2.54 (508) 1.31 (263) 0.78 (156) 0.31 (62) 6.10 (1220)   
5 0.4 200 0.34 (69) 0.31 (62) 1.65 (331) 0.82 (164) 0.72 (145) 0.22 (44) 4.07 (815)** 37.30 
10 0.4 200 0.41 (82) 0.39 (78) 1.63 (327) 0.91 (183) 0.67 (134) 0.20 (40) 4.22 (844)** 35.07 
25 0.4 200 0.23 (47) 0.16 (32) 0.90 (180) 0.44 (88) 0.39 (78) 0.09 (18) 2.21 (443)** 65.92 
50 0.4 200 0.10 (20) 0.13 (26) 0.53 (106) 0.22 (45) 0.20 (40) 0.07 (14) 1.25 (251)** 80.69 
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Appendice 2 
 
 
 
Figure 5. Schematic representation of the cross used in the Test for Detection of 
Epithelial Tumor Clones in Drosophila melanogaster. 
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Appendice 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
